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Abstract
Objectives: To quantify the impact of the implementation of treatment modalities into clinical practice since 1985, on
outcome of patients with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial
infarction (NSTEMI).
Methods: All consecutive patients admitted for STEMI or NSTEMI at the Thoraxcenter between 1985 and 2008 were
included. Baseline characteristics, pharmacological and invasive treatment modalities, and survival status were collected.
The study population was categorised in three groups of patients: those hospitalised between 1985–1990, 1990–2000, and
2000–2008.
Results: We identified 14,434 patients hospitalised for myocardial infarction (MI). Both STEMI and NSTEMI patients were
increasingly treated with the current guideline based therapy. In STEMI, at 30 days following admission, cumulative
mortality rate decreased from 17% in 1985–1990 to 13% in 1990–2000, and to 6% in 2000–2008. Adjusted 30-day and
three-year mortality in the last period was 80% and 68% lower than in 1985, respectively. In NSTEMI, at 30 days
following admission, cumulative mortality rate decreased from 6% in 1985–1990 to 4% in 1990–2000, and to 2% in
2000–2008. Adjusted 30-day and three-year mortality in the last period was 78% and 49% lower than in 1985,
respectively. For patients admitted between 2000 and 2008, 3 year survival of STEMI and NSTEMI patients was 87% and
88%, respectively.
Conclusions: Our results indicate substantial improvements in acute- and long-term survival in patients hospitalised for MI,
related to improved acute- as well as long-term treatment. Early medical evaluation in suspected MI and intensive early
hospital treatment both remain warranted in the future.
Citation: Nauta ST, Deckers JW, Akkerhuis M, Lenzen M, Simoons ML, et al. (2011) Changes in Clinical Profile, Treatment, and Mortality in Patients Hospitalised for
Acute Myocardial Infarction between 1985 and 2008. PLoS ONE 6(11): e26917. doi:10.1371/journal.pone.0026917
Editor: Giuseppe Biondi-Zoccai, University of Modena and Reggio Emilia, Italy
Received August 11, 2011; Accepted October 5, 2011; Published November 2, 2011
Copyright:  2011 Nauta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Erasmus Medical Center, Rotterdam, was the only source of funding for the present study. The funder had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: j.deckers@erasmusmc.nl
Introduction
During the last 25 years, the management of patients
presenting with an acute myocardial infarction (MI) has
undergone many transformations. Until 1984, treatment was
limited to providing symptomatic relief, and management of
complications as arrhythmia’s, acute heart failure, or post-
infarction angina. In the 1980s, the introduction of antithrom-
botic treatment with aspirin and intravenous (or intracoronary)
fibrinolysis resulted in significant mortality reductions in patients
with ST-segment elevation myocardial infarction (STEMI).[1] In
the nineties, pre-hospital identification (‘‘triage’’) of patients with
an acute myocardial infarction with an indication for reperfusion
therapy and subsequent immediate (pre-hospital) initiation of
thrombolytic treatment was introduced in some areas.[2,3]
Although more effective thrombolytic agents became avail-
able,[4] reperfusion of the infarct-related vessel often failed,[5]
and bleeding complications were a limiting factor of fibrino-
lyis.[6] Gradually, mechanical percutaneous techniques im-
proved, and in the last decade primary percutaneous coronary
intervention (PCI) became the treatment of choice in patients
presenting with a STEMI.[7,8]
In the same time period, patients with non-ST-elevation
myocardial infarction (NSTEMI) benefitted from improved anti-
thrombotic and anti-coagulant therapy,[9] better risk stratification
and tailored treatment with selective coronary revascularization in
high risk patients.[9,10,11,12] Additionally, effective secondary
prevention was introduced with aspirin, beta-blockers, statins, and
ACE inhibitors in subjects with LV dysfunction and, subsequently,
in high risk MI survivors.[13,14,15,16,17] In combination, all
these developments reshaped the treatment map of the patient
with an MI.[18,19,20]
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26917The impact of the implementation of all these treatment
modalities into clinical practice on outcome has not yet been fully
quantified. Therefore, we analysed changes in clinical practise,
treatment, and 30-day as well as three-year outcome in a
consecutive series of STEMI or NSTEMI patients admitted at
our institution, an academic tertiary referral center, between 1985
and 2008.
Methods
We included all consecutive patients aged .18 years admitted
for STEMI or NSTEMI to the Intensive Coronary Care Unit
(ICCU) of the Thoraxcenter, Erasmus University Medical
Center between June 1985 and December 2008. The Thor-
axcenter was the referral center for all PCIs in the Rotterdam
region until 2005 when a second hospital started a PCI
programme. Regional arrangements were made such that
patients with MI were referred to either hospital according to
a pre-arranged schedule.
The primary discharge diagnosis of MI was made in the
presence of the following characteristics: chest pain or equivalent
symptoms in combination with dynamic ECG changes consistent
with MI and a serial rise (to at least three times the upper normal
value) and fall in serum biochemical markers of cardiac necrosis
Table 1. Baseline characteristics, clinical presentation, and
discharge medication of patients hospitalised for STEMI
Period of admission P
1985-1990 1990-2000 2000-2008
No. of patients 947 1928 3945
Baseline
Age (years) 60611.6 60612.7 61612.6 0.01
Gender (male) 731 (77%) 1432 (74%) 2937 (75%) 0.20
Cardiac history
Previous MI 334 (35%) 463 (24%) 1075 (27%) ,0.001
Previous PCI 43 (5%) 127 (7%) 653 (17%) ,0.001
Previous CABG 83 (9%) 124 (6%) 282 (7%) 0.09
Risk factors
Hypertension 320 (34%) 549 (29%) 1295 (33%) ,0.01
Diabetes 79 (8%) 204 (11%) 571 (14%) ,0.001
Hyperlipidemia 76 (8%) 295 (15%) 919 (23%) ,0.001
Family history 201 (21%) 400 (21%) 1062 (27%) ,0.001
Current smoker 403 (43%) 675 (35%) 1518 (39%) ,0.001
Renal dysfunction 104 (11%) 229 (12%) 179 (5%) ,0.001
Anemia 309 (33%) 818 (42%) 1464 (37%) ,0.001
Medication at ICCU
discharge
Statin 0 (.) NA 2996 (76%) ,0.001
Aspirin 97 (10%) 1200 (62%) 3510 (89%) ,0.001
Beta-blocker 412 (44%) 958 (50%) 2341 (59%) ,0.001
Calcium antagonist 306 (32%) 315 (16%) 174 (4%) ,0.001
Nitrates 220 (23%) 241 (13%) 190 (5%) ,0.001
Diuretics 334 (35%) 306 (16%) 321 (8%) ,0.001
ACE inhibitor or ARB 0 (.) 403 (21%) 1308 (33%) ,0.001
ACE, Angiotensin-Converting Enzyme; ARB, Angiotensin receptor blocker;
CABG, coronary artery bypass grafting surgery; ICCU, intensive coronary care
unit; MI, myocardial infarction; NA, not available; PCI, percutaneous coronary
intervention; STEMI, ST-elevation MI.
doi:10.1371/journal.pone.0026917.t001
Figure 1. Treatment of STEMI patients over time
doi:10.1371/journal.pone.0026917.g001
Figure 2. Kaplan-Meier curves for 30-day cumulative mortality
(Figure 2A) or three-year cumulative survival (Figure 2B)
according to calendar period of admission
doi:10.1371/journal.pone.0026917.g002
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were diagnosed as STEMI in the presence of ST-segment
elevation . 0.1 mV in at least two peripheral leads, or .
0.2 mV in at least two precordial leads, and as NSTEMI
otherwise. For patients admitted more than once, only the first
hospitalisation was taken into account.
Data collection
This is a prospective observational study. Trained physicians
and nurses accustomed to the use of standardized case report
forms collected the data. Demographic characteristics (age,
gender), cardiac history (previous MI, PCI or coronary artery
bypass surgery [CABG]), risk factors (hypertension, diabetes,
family history, smoking status), renal dysfunction (creatinine value
.150 mmol/L), and pharmacological and invasive treatment
modalities (thrombolysis and PCI) were collected.
Figure 3. Adjusted odds or hazard ratios of secular trends in
mortality after STEMI at 30-days (Figure 3A), at 3-year
(Figure 3B), and at 3-year among 30-day survivors
(Figure 3C). The upper part of the figure compares changes in
mortality in time periods of three year, the lower part among patients
hospitalised between 1985–1990; 1990–2000; and 2000–2008 *Refer-
ence category for the subsequent ratios CI, confidence interval; HR,
Hazard ratio; OR, Odds ratio, STEMI, ST-elevation myocardial infarction
doi:10.1371/journal.pone.0026917.g003
Table 2. Baseline characteristics, clinical presentation, and
discharge medication of patients hospitalised for NSTEMI
Period of admission P
1985-1990 1990-2000 2000-2008
No. of patients 1269 2672 3673
Baseline
Age (years) 61610.3 63611.7 63611.8 ,0.001
Gender (male) 921 (73%) 1806 (68%) 2575 (70%) ,0.01
Cardiac history
Previous MI 581 (46%) 1050 (39%) 1290 (35%) ,0.001
Previous PCI 130 (10%) 356 (14%) 757 (21%) ,0.001
Previous CABG 196 (15%) 292 (12%) 390 (11%) ,0.001
Risk factors
Hypertension 455 (36%) 881 (34%) 1604 (44%) ,0.001
Diabetes 95 (8%) 321 (12%) 745 (20%) ,0.001
Hyperlipidemia 159 (13%) 736 (24%) 1785 (49%) ,0.001
Family history 331 (26%) 666 (25%) 1122 (31%) ,0.001
Current smoker 459 (36%) 741 (28%) 880 (24%) ,0.001
Renal dysfunction 102 (8%) 222 (8%) 349 (10%) 0.20
Anemia 489 (39%) 1153 (43%) 1783 (49%) ,0.001
Medication at ICCU
discharge
Statin 0 (.) NA 1962 (68%) ,0.001
Aspirin 225 (18%) 1169 (55%) 3125 (85%) ,0.001
Beta-blocker 865 (68%) 1271 (60%) 2334 (64%) ,0.001
Calcium antagonist 884 (70%) 972 (46%) 515 (14%) ,0.001
Nitrates 475 (37%) 393 (19%) 335 (9%) ,0.001
Diuretics 240 (19%) 276 (13%) 337 (9%) ,0.001
ACE inhibitor or ARB 0 (.) 191 (7%) 1134 (31%) ,0.001
ACE, Angiotensin-Converting Enzyme; ARB, Angiotensin receptor blocker;
CABG, coronary artery bypass grafting surgery; ICCU, intensive coronary care
unit; MI, myocardial infarction; NA, not available; NSTEMI, non-ST-elevation MI;
PCI, percutaneous coronary intervention.
doi:10.1371/journal.pone.0026917.t002
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The primary endpoint was all cause mortality at 30 days and at
three-years. In-hospital mortality was retrieved from the medical
records. Survival status was assessed through municipal Civil
Registries in 2010 and was available for 99% of all patients.
Ethics Statement
This study has been approved by the Ethical Committee of the
Erasmus Medical Center, Rotterdam. According to Dutch laws,
informed consent is not required for register-based research of pre-
existing personal data. Therefore, the Ethical Committee waived
the need for informed consent.
Statistical Analysis
Data are summarized as frequencies and percentages for
categorical variables. Continuous variables are presented as mean
and standard deviation or median and 25th and 75th percentile.
The study population was categorised in three groups of patients,
those hospitalised between 1985–1990; 1990–2000; and 2000–
2008, respectively. These categories were chosen according to
important improvements in therapy with complete introduction of
thrombolysis in 1991 and substantial increase in the use of primary
PCI in 2001. Categorized variables among the three groups were
compared with the chi-square test and continuous variables by
ANOVA with Bonferroni corrections. In addition, we compared
changes in mortality in time periods of three year, and these
changes are presented in Forrest plots.
Cumulative survival and one-minus-survival curves were
constructed using the Kaplan–Meier method according to date
of hospitalization as presented above. A log-rank test was used to
compare survival curves. We examined the independent associ-
ation between year of hospitalization and mortality using logistic
regression for 30-day outcome and the Cox proportional hazards
model for long-term outcome, with adjustment for age, gender,
previous MI, previous CABG, diabetes, hypertension and
smoking status. Results are reported as odds or hazard ratios of
mortality and their respective 95% confidence intervals. Propor-
tionality of hazards was tested graphically by inspection of log–
log survival curves and by a formal test of proportionality based
on Schoenfeld residuals for each variable in the model.
Calibration refers to whether the model agrees with the observed
probabilities and was assessed with the Hosmer–Lemeshow
statistic.
All statistical tests were 2-tailed, and p-values were significant at
,0.05. Analysis was performed using SPSS software version 17.0
(SPSS, Chicago, USA).
Results
We identified 14,434 consecutive patients hospitalised for MI in
our center between 1985 and 2008: 6,820 STEMI and 7,614
NSTEMI patients. At three years follow-up, mortality had
occurred in 2,190 patients, 1,232 in STEMI and 958 in NSTEMI
patients.
ST-segment elevation myocardial infarction
The characteristics of the STEMI patients are depicted in
Table 1. With time, STEMI patients presented older, were more
likely to have diabetes, hyperlipidemia, anemia, and a history of
PCI. Further, STEMI patients were less likely to present with renal
dysfunction or a history of MI.
The percentage of STEMI patients treated with PCI increased
gradually. Before 1985, neither intracoronary- nor intravenous
thrombolytic therapy was employed, while intravenous fibrinolysis
was the main treatment modality from 1985 to 1998. From 1998
onwards, treatment with thrombolysis was gradually replaced by
primary PCI (Figure 1). Since our institution was initially the only
hospital with PCI facilities in the region, the number of patients
with STEMI admitted increased as a result of the decision to offer
primary PCI to all STEMI patients in the Rotterdam Region. In
the most recent cohort, drug therapy with aspirin, beta-blockers,
statins, and ACE inhibitors or angiotensin receptor blockers was
quite common, but calcium antagonists, diuretics or nitrates were
prescribed less frequently.
At 30 days following admission, cumulative mortality rate
decreased from 17% in 1985-1990 to 13% in 1990-2000, and to
6% in 2000-2008 (p,0.001; Figure 2). Adjusted 30-day mortality
in the last period was 80% lower than in 1985 (adjusted odds ratio
[OR] 0.20, 95%CI 0.14-0.28, p,0.001) (Figure 3).
Cumulative three-year survival rate increased from 73% in
1985-1990 to 75% in 1990–2000 and to 87% in 2000–2008
(p,0.001). Adjusted three-year mortality in the last period was
68% lower than in 1985 (adjusted hazard ratio [HR] 0.32, 95%CI
0.26–0.40, p,0.001). In a landmark analysis, including only
Figure 4. Kaplan-Meier curves for 30-day cumulative mortality
or (Figure 4A) or three-year cumulative survival (Figure 4B)
according to calendar period of admission
doi:10.1371/journal.pone.0026917.g004
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mortality was 57% lower in the most recent period than in 1985
(adjusted HR 0.43, 95%CI 0.31-0.58, p,0.001, Figure 3).
Non-ST-segment elevation myocardial infarction
With time, NSTEMI patients presented older, were more likely
to have hypertension, diabetes, hyperlipidemia, or anemia and less
likely to be a smoker (Table 2). Furthermore, NSTEMI patients
more often presented with a history of PCI and less often
presented with a history of MI in the most recent study period. As
in STEMI, prescription of aspirin, beta-blockers, statins, and ACE
inhibitors or angiotensin receptor blockers increased while the use
of calcium antagonists and nitrates decreased.
At 30 days following admission, cumulative mortality rate
decreased from 6% in 1985-1990 to 4% in 1990–2000, and to 2%
in 2000–2008 (p,0.001; Figure 4). Adjusted 30-day mortality in
the last period was 78% lower than in 1985 (adjusted OR 0.22,
95%CI 0.13–0.37, p,0.001; Figure 5).
Cumulative three-year survival rate did not significantly change
between 1985-1990 (85%) and 1990-2000 (86%). Three-year
survival in the last period was 88% (p,0.001). Adjusted three-year
mortality in the last period was 49% lower than in 1985 (adjusted
HR 0.51, 95%CI 0.39-0.68, p,0.001). In a landmark analysis,
including only patients who survived the first 30 days, adjusted
three-year mortality was 29% lower in the most recent period than
in 1985 (adjusted HR 0.71, 95%CI 0.52-0.99, p=0.042, Figure 5).
For patients admitted between 2000 and 2008, long term
survival of STEMI and NSTEMI patients was comparable, 87%
and 88%, respectively (Figures 2 and 4). The higher subsequent
mortality in non-STEMI patients resulted from their older age.
After correction for this confounder, the risk of 30-day to three-
year mortality was similar in NSTEMI and STEMI (adjusted HR
1.0, 95%CI 0.86-1.2).
Discussion
We have shown that, during a period of almost 25 years, overall
30 day mortality in patients hospitalised for MI was reduced with
80%. In patients admitted for ST-segment elevation MI (STEMI),
30-day mortality declined from 17% to 6%. In patients with a
smaller, non ST-segment elevation MI (NSTEMI) 30-day
mortality declined from 6% to 2%. In addition, we demonstrated
that this early survival benefit was maintained over three years of
follow-up, with long term survival increasing from 73% to 87%
and from 85% to 88% in STEMI and NSTEMI, respectively. The
reduction in long- term all-cause mortality is illustrative of the
strength of the improvement of the combined treatment effects.
There can be little doubt that such improvements have resulted
from changes in medical therapy, both pharmacological as well as
interventional.[20] The most important factors must have been
the introduction of reperfusion therapy in the form of fibrinolytic
therapy and later primary PCI for STEMI,[1,8] as well as the
more frequent use of revascularization in selected patients with
NSTEMI. Also, the introduction and subsequent employment of
medical therapies including statins, and ACE inhibitors or
angiotensin receptor blockers must have played a role. Of course,
patient characteristics also gradually changed during the observa-
tion period. However, most of the observed alterations in our
patient’s phenotypes, like increasing age and more co-morbidity
such as diabetes and renal dysfunction, have previously been
Figure 5. Adjusted odds or hazard ratios of secular trends
in mortality after NSTEMI at 30- days (Figure 5A), at
3-year (Figure 5B), and at 3-year among 30-day survivors
(Figure 5C). The upper part of the figures compares changes in
mortality in time periods of three year, the lower part among
patients hospitalised between 1985–1990; 1990–2000; and 2000–
2008 *Reference category for the subsequent ratios CI, confidence
interval; NSTEMI, non-ST-elevation myocardial infarction; HR, Hazard
ratio; OR, Odds ratio
doi:10.1371/journal.pone.0026917.g005
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observed outcome improvement. A reduction in case fatality in
spite of treating older patients with co-morbidity has also been
observed in other observational studies.[20,21,22] Earlier clinical
presentation could have contributed to improved prognosis, but
we found no evidence for this.
Better primary prevention could have influenced the severity of
the acute clinical event, and better secondary prevention must also
have contributed significantly. Exact details of the medication use
of our patients after discharge are not known, but registries in our
region in 1995, 2001 and 2006 indicated that the use of preventive
medication significantly intensified during that time.[14] For
instance, statins were used by 36%, 72% and 93% of the patients
respectively, with a subsequent drop in mean cholesterol level from
6.2 mmol/l in 1995 to 4.2 mmol/l in 2006. Aspirin was used by
.90% of the patients from 1995 onwards, and smoking trends
decreased from 32% to 15% between 1995 and 2006.[14]
With time, the number of patients admitted with myocardial
infarction increased. This was mainly the result of changes in
referrals: when primary PCI became the treatment of choice in
STEMI patients, they were specifically referred to our center from
2000 onwards. Our STEMI patients can therefore be considered
to be representative for this syndrome and we thus believe that the
decrease in mortality in this group is broadly illustrative of current
clinical practice. The number of NSTEMI patients also increased.
Most likely, this was also due to changes in referrals, in particular
of high risk patients in whom invasive therapy was warranted.
Therefore, our population with this type of acute coronary
syndrome will probably be less representative for that group at
large. Still, given their already low mortality, the further decline in
30-day mortality in this group with time was also impressive.
Other studies, such as The National Registry of Myocardial
Infarction, Worcester Heart Attack Study and Minnesota Heart
Survey,[19,20,23,24,25,26,27,28] have described prognostic time
trends after acute MI, but none of these covered both i) secular
trends for a period longer than 10 years from 1990 and ii) follow-
up data after the first 30-days; as the present study does.
Although the present study thus has unique strengths, some of
its limitations must be emphasized. First, the present data are
derived from a single center. Although this will have enhanced the
quality of the data and the observed secular trends, this could
result in a lower external validity. However, this is unlikely, since a
nation wide study in Sweden and a state wide study in the US
reported quite comparable results.[21,29] Second, based on our
data, it is not possible to establish changes in MI incidence as other
studies have shown. Still, the increasing age of our population
provides indirect evidence of a lower incidence rate of myocardial
infarction. Lastly, the current report is based on hospitalised
patients, and we are therefore unable to assess the changes in
mortality of all patients who suffered a myocardial infarction but
died before clinical presentation.
Conclusions
Our results indicate very substantial improvements in acute and
long term survival in patients hospitalised for MI, related to
improved acute- as well as long-term treatment. Since the early
survival benefit is maintained over time, the present results
emphasize that efforts to further reduce in-hospital mortality must
be rigorously pursued, and that early medical evaluation in
suspected MI and intensive early hospital treatment remain
warranted. Although one might envisage even lower hospital
mortality rates associated with acute MI in the future, absolute
treatment benefits will become smaller because of the current low
mortality levels. Indirectly therefore, our data emphasize the need
for better and more effective primary prevention, as well as the
necessity to target high risk MI subgroups such as the elderly and
those with heart failure.
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